AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
A securities class action alleges former Chief Operating Officer Bryan Jones, Ph.D. told investors in May 2025 that ARD-101 had a "very, very clean" safety profile, months before cardiac observations allegedly forced a Phase 3 pause and a full FDA clinical hold. NEW YORK, Oct. 7, 2026...
Covered in this story
What has happened since
- Aardvark Therapeutics Inc is down 21.4% since this was published, 13 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $AARD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aardvark Therapeutics Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.